|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
IDM S.A. Will Present Phase II Trial Results For Its Melanoma Cancer Vaccine, Uvidem, At American Society of Clinical Oncology - Orlando - On May 15, 2005
10/19/2005 5:10:30 PM
PARIS, France--(BUSINESS WIRE)--May 5, 2005--IDM (Immuno-Designed Molecules), a biopharmaceutical company which recently announced a business combination with Epimmune Inc. (Nasdaq : EPMN), will present the results of a phase II trial of its cancer vaccine, Uvidem(R), for the treatment of patients with melanoma, at the Annual Meeting of ASCO (American Society of Clinical Oncology) in Orlando, Florida. This presentation will be given on May 15, 2005, as part of the "Immunotherapy General Poster Session" program, from 8 AM to 12 PM.
Uvidem is a therapeutic vaccine developed by IDM in partnership with Sanofi-Aventis. It consists of dendritic cells loaded with lysates prepared from melanoma cell lines. The phase II trial to be presented included 60 patients with stage IV melanoma and was conducted at 12 clinical centers in France and Australia. The primary endpoint of this trial was to assess the safety and immune response following this treatment.
|
|
|
|
|
|
|
|
|
|
|